These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21669387)

  • 1. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
    Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
    Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on "early dialogue" between a manufacturer and health technology assessment agencies.
    Geisler BP
    Value Health; 2011 Jun; 14(4):607. PubMed ID: 21669386
    [No Abstract]   [Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology assessment: approach and reimbursement.
    Yaszemski MJ; Polly DW; Boden SD; Andersson GB
    Spine (Phila Pa 1976); 2007 May; 32(11 Suppl):S39-43. PubMed ID: 17495585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
    Ijzerman MJ; Steuten LM
    Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early scientific advice obtained simultaneously from regulators and payers: findings from a pilot study in Australia.
    Wonder M; Backhouse ME; Hornby E
    Value Health; 2013; 16(6):1067-73. PubMed ID: 24041357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review.
    Hartz S; John J
    Int J Technol Assess Health Care; 2008; 24(4):465-72. PubMed ID: 18828942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
    Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
    Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditionally funded field evaluations and practical trial design within a health technology assessment framework.
    Bowen JM; Patterson LL; O'Reilly D; Hopkins RB; Blackhouse G; Burke N; Xie F; Tarride JE; Goeree R
    J Am Coll Radiol; 2009 May; 6(5):324-31. PubMed ID: 19394573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Innovation in health care: the role of HTA in the introduction of new technologies].
    Bührlen B
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):703-8. PubMed ID: 21147431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changing role of economic evaluation in valuing medical technologies.
    Rotter JS; Foerster D; Bridges JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare payment for new technologies. Can the process be improved despite conflicting goals? An ECRI technology management assessment.
    J Health Care Technol; 1986; 3(1):13-32. PubMed ID: 10300959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reimbursement programs and health technology assessment for diabetes devices and supplies: a Canadian perspective.
    Cheung RY; Mui V
    J Diabetes Sci Technol; 2015 May; 9(3):706-10. PubMed ID: 25697719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.